EUCTR2020-001784-88-FI进行中（未招募）1 期
WHO SOLIDARITY Finland: The multicenter trial on the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19) - SOLIDARITY Finland
niversity of Helsinki0 个研究点目标入组 582 人开始时间: 2020年4月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 582
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Adult patients, 18 years and above
- •2. Confirmed SARS-2-CoV-2 infection by PCR
- •3. Admitted to the hospital ward or the ICU
- •4. Subjects (or legally authorized representative) provides written
- •informed consent prior to initiation of the study
- •5. No anticipated transfer within 72 hours to a non-study hospital
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 291
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 291
排除标准
- •1.Severe co-morbidity with life expectancy <3 months according to investigators assessment
- •2.ASAT/ALAT > 5 times the upper limit of normal
- •3.Acute co-morbidity within 7 days before inclusion such as myocardial infarction or UAP (not including troponin elevation due to infection)
- •4.Known intolerance to the available study drugs
- •5.Pregnancy or breast feeding
- •6.Any reason why, in the opinion of the investigators, the patient should not participate
- •7.Subject participates in a potentially confounding drug or device trial during the course of the study
- •8.Already receiving any of the study drugs
- •9.Renal failure (eGRF < 30 mL/min) or dialysis or continuous veno-venous hemofiltration
研究者
相似试验
进行中（未招募）
1 期
A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19).SARS-COV-2 infectionMedDRA version: 21.1Level: LLTClassification code 10037373Term: Pulmonary disorderSystem Organ Class: 100000004855EUCTR2020-000982-18-SEKarolinska University hospital1,218
进行中（未招募）
不适用
Multi-center, Multi-national Clinical Trial of the Application of Tissue Repair Cell (TRC) Therapy of Osteonecrosis in the Femur HeadEUCTR2006-001286-42-ESAastrom Biosciences, Inc15
进行中（未招募）
1 期
Trial of efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) in patients with previously treated, advanced cervical cancerrecurrent or metastatic cervical cancerMedDRA version: 21.1Level: PTClassification code 10008342Term: Cervix carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003413-25-CZGenmab A/S100
进行中（未招募）
1 期
Trial of efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) in patients with previously treated, advanced cervical cancerrecurrent or metastatic cervical cancerMedDRA version: 21.1Level: PTClassification code 10008342Term: Cervix carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003413-25-DKGenmab A/S100
进行中（未招募）
1 期
Trial of efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) in patients with previously treated, advanced cervical cancerrecurrent or metastatic cervical cancerMedDRA version: 20.0Level: PTClassification code 10008342Term: Cervix carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003413-25-ESGenmab A/S100